Antimicrobial Peptide, LL-37, And Its Potential As An Anti-HIV Agent

Clin Invest Med. 2021 Oct 3;44(3):E64-71. doi: 10.25011/cim.v44i3.36657.

Abstract

Human immunodeficiency virus (HIV) continues to have a profound global health impact. New infections continue at a high rate despite the development of prophylactic therapies, prompting the need for development of novel preventative approaches. Antimicrobial peptides (AMPs), such as LL-37, display broad microbicidal properties and have potential as anti-HIV agents. LL-37 has been studied for its anti-HIV activity and the limited data available suggest it can inhibit HIV infection in primary T cells as well as exert inhibitory effects on key HIV enzymes. Its immunomodulatory properties may both enhance and inhibit HIV replication. In addition, LL-37 has both 1) the ability to kill other sexually-transmitted pathogens and 2) spermicidal activity; thus, it is a good candidate for multipurpose prevention technology. Further investigation of its anti-HIV activity is warranted.

Keywords: antimicrobial; antimicrobial peptides; anti-HIV; review.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents
  • Anti-HIV Agents*
  • Antimicrobial Cationic Peptides*
  • Cathelicidins
  • Pore Forming Cytotoxic Proteins

Substances

  • Anti-Bacterial Agents
  • Anti-HIV Agents
  • Antimicrobial Cationic Peptides
  • Cathelicidins
  • Pore Forming Cytotoxic Proteins